Kumar Roshan, Sood Utkarsh, Gupta Vipin, Singh Mona, Scaria Joy, Lal Rup
PhiXGen Private Limited, Gurugram, Haryana 122001 India.
2Department of Veterinary and Biomedical Sciences, South Dakota State University, Brookings, SD USA.
Indian J Microbiol. 2020 Mar;60(1):12-25. doi: 10.1007/s12088-019-00808-y. Epub 2019 May 25.
A healthy gut is predominantly occupied by bacteria which play a vital role in nutrition and health. Any change in normal gut homeostasis imposes gut dysbiosis. So far, efforts have been made to mitigate the gastrointestinal symptoms using modern day probiotics. The majority of the probiotics strains used currently belong to the genera , , and . Recent advancements in culturomics by implementing newer techniques coupled with the use of gnotobiotic animal models provide a subtle ground to develop novel host specific probiotics therapies. In this review article, the recent advances in the development of microbe-based therapies which can now be implemented to treat a wide spectrum of diseases have been discussed. However, these probiotics are not classified as drugs and there is a lack of stringent law enforcement to protect the end users against the pseudo-probiotic products. While modern probiotics hold strong promise for the future, more rigorous regulations are needed to develop genuine probiotic products and characterize novel probiotics using the latest research and technology. This article also highlights the possibility of reducing antibiotic usage by utilizing probiotics developed using the latest concepts of syn and ecobiotics.
健康的肠道主要由细菌占据,这些细菌在营养和健康方面发挥着至关重要的作用。正常肠道内环境稳定的任何变化都会导致肠道生态失调。到目前为止,人们已努力使用现代益生菌来减轻胃肠道症状。目前使用的大多数益生菌菌株属于 、 、 和 属。通过采用更新技术结合使用悉生动物模型,文化组学的最新进展为开发新型宿主特异性益生菌疗法提供了微妙的基础。在这篇综述文章中,讨论了基于微生物的疗法的最新进展,这些疗法现在可用于治疗多种疾病。然而,这些益生菌未被归类为药物,并且缺乏严格的执法来保护终端用户免受伪益生菌产品的侵害。虽然现代益生菌对未来充满希望,但需要更严格的法规来开发真正的益生菌产品,并利用最新的研究和技术对新型益生菌进行表征。本文还强调了利用基于合生元和生态益生菌最新概念开发的益生菌来减少抗生素使用的可能性。